Connecticut · Nonprofit
THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC
THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC (Connecticut) receives grants from 484 organizations whose IRS filings report $57,375,530 to it, the largest being FIDELITY INVESTMENTS CHARITABLE GIFT FUND ($9,165,931). 236 of them have funded it in more than one year, and 55% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- Revenue FY2025
- $37M
- Funders on record
- 484
- Grants received
- $57M
- Net assets
- $48M
What The Multiple Myeloma Research Foundation Inc does
Mission
The multiple myeloma research foundation (mmrf) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the mmrf has committed over $600 million for research, supported nearly 100 clinical trials and research studies, and helped bring over 15 fda-approved therapies to market, which have tripled the life expectancy of myeloma patients.
As stated on its FY2025 Form 990.
Programs
The multiple myeloma research consortium (mmrc), the clinical research subsidiary of the multiple myeloma research foundation (mmrf), is a collaborative network of leading cancer centers driving cutting-edge clinical trials. The mmrf launched the horizon clinical trials program through the mmrc to drive progress for patients who need it most. Horizon trials use an adaptive platform design that allows researchers to test several treatments at the same time and add new options as data becomes available. In 2025, the horizon one trial focused on relapsed/refractory myeloma exceeded many of its enrollment goals for its first treatment arm, which is testing dosing approaches for a bispecific antibody. The trial so far has enrolled more black patients and older adultstwo groups that have historically been left out of researchthan most myeloma trials. Horizon one became the first-ever myeloma clinical trial in flint, michigan, and it opened at 25 community hospitals and clinics last year. Also in 2025, 13 sites entered the start-up phase in the horizon two clinical trial focused on high-risk, newly diagnosed myeloma so they could fully open and begin screening patients in 2026.
$6,096,220 spent$8,674,361 earned by the program22% of program spendingData helps drive every breakthrough in myeloma. By building and sharing large, high-quality datasets, the mmrf is creating a launchpad for the next wave of treatments, improvements in care, and, ultimately, cures. In 2025, the mmrf launched its next innovation in data sharing: the mmrf virtual labtm. Virtual lab is now myeloma's largest, most-comprehensive data-sharing platform and brings all the mmrf's data into one place. The platform and its robust data will empower researchers to ask bigger questions, test new hypotheses, and accelerate discoveries that improve outcomes for patients with myeloma.
$2,669,588 spent10% of program spendingThe mac program provides $21 million over 3 years to create multicenter translational research teams across global medical centers. Each of these three-year multicenter translational projects aim to foster collaboration and advance compelling hypotheses that are ready for rapid testing in clinical trials, a critical step in the mmrf's urgent pursuit of a cure for each and every myeloma patient. The grants are focused on two critical areas of unmet need: optimizing first-line therapy for newly diagnosed high-risk myeloma and improving identification of high-risk smoldering myeloma (hr smm), an early, asymptomatic stage that can proceed to active myeloma. In 2025 the collaborating centers continued to make positive progress, showing that pooling resources and samples across a network of institutions dramatically improves the ability to drive meaningful results.
$1,600,000 spent6% of program spendingBeyond the program expenses outlined above, the mmrf also supports a range of strategic initiatives aligned with its broader mission. This includes a robust portfolio of cutting-edge basic science and translational research aimed at identifying new therapeutic targets through genomics and proteomics; validation studies to explore promising compounds and treatment combinations; and innovative clinical trials focused on novel and combination therapies.founded by patients, the mmrf is deeply committed to those impacted by myeloma: patients, families, physicians, researchers, and investors. At the same time, the mmrf distinguishes itself through its bold and collaborative approach. We generate, analyze, and share the largest, most comprehensive set of high-quality myeloma data, making it publicly available to accelerate progress. By bringing together the right people, programs, and technologies, the mmrf is driving the rapid discovery of cures for each and every patient.
$16,987,283 spentof which $3,576,906 as grants$70,864 earned by the program62% of program spending
The 4 programs described on its FY2025 Form 990, listed largest first by expense. Program spending in total: $27,353,091.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2023 to 2024, from $80M to $66M (−17%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2021 3% · 2024 0%. Grants only. Government contracts and fees sit inside program revenue.
73% of THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC’s revenue is contributions — more reliant on donations than three-quarters of its peers (7% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 3 of the last 9 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
Michael Andreini
President & CEO
Board chair
Thomas Conheeney
Chairman
As listed on its FY2025 Form 990.
The chief executive listed changed between the FY2020 and FY2021 filings.
Who funds it, year by year
2017 → 2023: the base broadened from 105 funders to 172 funders, grant income rose $2.9M → $7.1M.
57 of 484 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 55% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC’s funders (the co-funder graph). Top 30 of 484 funders by total. Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC has a broad base — no single funder exceeds 16% of grant income, and it takes 7 funders to reach half.
the vertical line marks half of all grant income — 7 funders to its left
58% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC.
Largest funder’s share by year: 2017 23% · 2018 32% · 2019 41% · 2020 32% · 2021 28% · 2022 19% · 2023 31% — growing more concentrated.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
30% of THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC's funders are still giving 3 years after their first grant; 49% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
55% of THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC's grant income arrives through donor-advised or pass-through sponsors, whose addresses record where the money is held rather than where the donor is. Of the $26M that is directly attributable, 98% of it comes from funders outside Connecticut, across 36 states.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $32M arriving through sponsors registered in 24 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC holds deeper cash reserves than three-quarters of the 2,969 health nonprofits its size.
this organization peer median middle 50% of peers· 2,969 health nonprofits $10M–$100M, FY2025
Organizations like THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Connecticut
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
79% of spending goes to programs.
Governance
Public support
88%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 25 states
Part of a family of 2 related entities
- Myeloma Investment Fund LLC · disregarded
- Multiple Myeloma Research Consortium LLC · disregarded
Screen this organization
A dated, signed PDF of the compliance screen for THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC?
- THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC (Connecticut) receives grants from 484 organizations whose IRS filings report $57,375,530 to it, the largest being FIDELITY INVESTMENTS CHARITABLE GIFT FUND ($9,165,931). 236 of them have funded it in more than one year, and 55% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- How many funders does THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC have?
- IRS filings report 484 organizations giving $57,375,530 in grants to THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC, 236 of which have funded it in more than one year.
- Who is the largest funder of THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC?
- FIDELITY INVESTMENTS CHARITABLE GIFT FUND is the largest funder on record, with $9,165,931 in grants. The full list of funders is on this page.
- How can an organization like THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Connecticut. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2025 (financials across 2017–2025), and the filings of 484 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 22, 2026. What this page cannot tell you · view filing